Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.45 |
| ▸ | CA2 | P00918 | 5/20 | 0.45 |
| ▸ | CA9 | Q16790 | 5/20 | 0.45 |
| ▸ | CA1 | P00915 | 4/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10053489 | 0.72 | CA12 (0.61) | CA12CA2CA9CA1HDAC4 | |
| SCHEMBL13484009 | 0.69 | ALDH1A1 (0.46) | CA12CA2CA9CA1 | |
| SCHEMBL1770347 | 0.68 | CA12 (0.53) | CA12CA2CA9CA1HDAC4 | |
| SCHEMBL7902178 | 0.68 | CA12 (0.56) | CA12CA2CA9CA1LRRK2 | |
| SCHEMBL3602297 | 0.67 | ADORA2A (0.34) | HDAC4PIK3CG | |
| SCHEMBL10022410 | 0.66 | CA12 (0.54) | CA12CA2CA9CA1LRRK2 | |
| SCHEMBL12499177 | 0.66 | CA12 (0.39) | CA12CA2CA9CA1HDAC4 | |
| SCHEMBL6261333 | 0.64 | CA12 (0.55) | CA12CA2CA9CA1PIK3CG | |
| SCHEMBL344598 | 0.63 | ALOX15 (0.59) | CA12CA2CA9CA1HDAC4 | |
| SCHEMBL18741079 | 0.63 | NPC1 (0.38) | ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642642-B2 | Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor | ABBOTT LABORATORIES (US) | 2014-02-04 | — | — | US | disclosed |
| US-8497273-B2 | Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-07-30 | — | — | US | disclosed |
| US-20100048582-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20090306175-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2009-12-10 | — | — | US | disclosed |
| EP-2074110-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2009-07-01 | — | — | EP | disclosed |
| EP-2029528-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007118900-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007118899-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306175-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | HTR6, HTR1A, HTR5A | CA12 4595/4885CA2 3573/4885CA9 4875/4885 |
| US-20100048582-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | HTR6, HTR1A, HTR2C | CA12 3778/4885CA2 2814/4885CA9 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.